MI SB0094

Prohibits drug manufacturers, wholesalers, and wholesale distributor-brokers from denying, restricting, or discriminating against 340B entities or their contracted pharmacies in acquiring or receiving 340B drugs

Requires 340B entities to submit annual reports to the Department of Health beginning July 1, 2026, including their program recertification, community health needs assessment (if applicable), compliance affidavits, and descriptions of program impact on patients and communities

Mandates drug manufacturers report annually on prescription drugs costing over $40 per treatment course that have increased wholesale acquisition cost by more than 15% in the preceding 12 months

Manufacturer reports must include drug production costs, wholesale acquisition cost history for 5 years, patent expiration dates, market introduction dates, and dispensing forms

Department must publish all submitted reports on its publicly accessible website; bill is contingent on passage of companion legislation (SB 95 or HB with request no. H00977'25)